348-P: Nasal Glucagon Was Efficacious in Reversing Insulin-Induced Hypoglycemia across a Range of Nadir Blood Glucose Levels

Abstract

Background: Nasal glucagon (NG) is a ready-to-use rescue treatment for severe hypoglycemia. We evaluated efficacy and safety of NG in reversing insulin-induced hypoglycemia for a range of nadir blood glucose (BG) levels in adults with T1D or T2D. Methods: Post-hoc analyses included data from 3 randomized, cross-over studies. BG response, treatment success, and treatment-emergent adverse events (TEAE) were evaluated across nadir (baseline) BG levels for NG and reconstituted injectable glucagon (IG). Treatment success was defined as an increase in BG to ≥70 mg/dL or increase of ≥20 mg/dL from nadir within 30 min of receiving glucagon. Results: A similar proportion of NG (99.5% [213/214]) and IG participants (100% [214/214]) achieved treatment success. Mean times from glucagon administration to BG increase of ≥20 mg/dL for nadir BG categories of Conclusion: NG was well-tolerated and efficacious in reversing insulin-induced hypoglycemia across various nadir BG levels. Disclosure J. Yale: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Novo Nordisk Canada Inc., Sanofi, Research Support; Self; Bayer Inc., Speaker’s Bureau; Self; Dexcom, Inc., Medtronic, Merck & Co., Inc., Omnipod. R. J. Threlkeld: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. Q. Wang: Employee; Self; Eli Lilly and Company. P. Garhyan: Employee; Self; Eli Lilly and Company. D. James: None. C. J. Child: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. Y. Yan: Employee; Self; Eli Lilly and Company. Funding Eli Lilly and Company